Showing results (221-230 of 781) with videos related to

Sort By:
Pageof 79
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
The emerging role of novel therapies for the treatment of relapsed myelomaPaul G Richardson, Teru Hideshima, Constantine Mitsiades, et al.
Expert Review of Anticancer Therapy|August 24, 2006
Lenalidomide in multiple myelomaPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Expert Opinion on Investigational Drugs|October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignanciesKlaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivoHiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine WarheadsKrista Kinneer, John Meekin, Arnaud C Tiberghien, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
Annual Review of Medicine|January 18, 2006
Bortezomib: proteasome inhibition as an effective anticancer therapyPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.
Current Pharmaceutical Biotechnology|November 2, 2006
Recent advances in the treatment of Multiple MyelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.
Nature Communications|February 14, 2024
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myelomaJiye Liu, Lijie Xing, Jiang Li, et al.
Cancer Genomics & Proteomics|March 9, 2012
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growthJagannath Pal, Mariateresa Fulciniti, Puru Nanjappa, et al.
Pageof 79